Literature DB >> 31620855

Surveillance imaging in pediatric lymphoma.

Stephan D Voss1, Mitchell S Cairo2.   

Abstract

Current therapies used in treating children with Hodgkin lymphoma and many histological subtypes of non-Hodgkin lymphoma have resulted in overall survival rates exceeding 90% in many instances. With increasing concerns related to the cost of radiologic imaging, exposure to ionizing radiation, and potential false-positive results, the role of routine off-therapy surveillance imaging has been called into question. Although radiologic imaging plays an important role in diagnosing and assessing treatment response, in these children - the majority of whom have an excellent outcome following completion of therapy - there is an opportunity to dramatically reduce the number of off-therapy imaging evaluations. This review summarizes several recent studies in both Hodgkin and non-Hodgkin lymphoma providing evidence to support these efforts. In addition, we propose a surveillance imaging strategy that uses a novel risk-adapted and response-based approach to determine which children would most benefit from off-therapy imaging surveillance.

Entities:  

Keywords:  Children; Computed tomography; Hodgkin lymphoma; Late effects; Non-Hodgkin lymphoma; Positron emission tomography; Response-based surveillance; Risk-adapted surveillance; Surveillance imaging

Year:  2019        PMID: 31620855     DOI: 10.1007/s00247-019-04511-4

Source DB:  PubMed          Journal:  Pediatr Radiol        ISSN: 0301-0449


  40 in total

1.  Results of the AHOD0431 trial of response adapted therapy and a salvage strategy for limited stage, classical Hodgkin lymphoma: A report from the Children's Oncology Group.

Authors:  Frank G Keller; Sharon M Castellino; Lu Chen; Qinglin Pei; Stephan D Voss; Kathleen M McCarten; Stacy L Senn; Allen B Buxton; Rizvan Bush; Louis S Constine; Cindy L Schwartz
Journal:  Cancer       Date:  2018-05-08       Impact factor: 6.860

Review 2.  Non-Hodgkin Lymphoma in Children.

Authors:  John T Sandlund
Journal:  Curr Hematol Malig Rep       Date:  2015-09       Impact factor: 3.952

3.  Risk of solid subsequent malignant neoplasms after childhood Hodgkin lymphoma-Identification of high-risk populations to guide surveillance: A report from the Late Effects Study Group.

Authors:  Anna S Holmqvist; Yanjun Chen; Jennifer Berano Teh; Canlan Sun; Jillian M Birch; Cor van den Bos; Lisa R Diller; Kimberley Dilley; Jill Ginsberg; Laura T Martin; Rajaram Nagarajan; Paul C Nathan; Joseph P Neglia; Monica Terenziani; David Tishler; Anna T Meadows; Leslie L Robison; Odile Oberlin; Smita Bhatia
Journal:  Cancer       Date:  2018-12-17       Impact factor: 6.860

Review 4.  Late Effects Following Treatment of Hodgkin Lymphoma During Childhood and Adolescence. Results of the Hodgkin Lymphoma Late Effects Research Project.

Authors:  W Dörffel; M Riepenhausen; H Lüders; J Brämswig
Journal:  Klin Padiatr       Date:  2016-11-15       Impact factor: 1.349

5.  International Pediatric Non-Hodgkin Lymphoma Response Criteria.

Authors:  John T Sandlund; R Paul Guillerman; Sherrie L Perkins; C Ross Pinkerton; Angelo Rosolen; Catherine Patte; Alfred Reiter; Mitchell S Cairo
Journal:  J Clin Oncol       Date:  2015-05-04       Impact factor: 44.544

6.  Sequential myeloablative autologous stem cell transplantation and reduced intensity allogeneic hematopoietic cell transplantation is safe and feasible in children, adolescents and young adults with poor-risk refractory or recurrent Hodgkin and non-Hodgkin lymphoma.

Authors:  P Satwani; Z Jin; P L Martin; M Bhatia; J H Garvin; D George; S Chaudhury; J Talano; E Morris; L Harrison; J Sosna; M Peterson; O Militano; S Foley; J Kurtzberg; M S Cairo
Journal:  Leukemia       Date:  2014-06-18       Impact factor: 11.528

Review 7.  Childhood, adolescent and young adult non-Hodgkin lymphoma: state of the science.

Authors:  Mitchell S Cairo; Ross Pinkerton
Journal:  Br J Haematol       Date:  2016-05-02       Impact factor: 6.998

8.  Breast cancer and other second neoplasms after childhood Hodgkin's disease.

Authors:  S Bhatia; L L Robison; O Oberlin; M Greenberg; G Bunin; F Fossati-Bellani; A T Meadows
Journal:  N Engl J Med       Date:  1996-03-21       Impact factor: 91.245

9.  Cause-specific mortality and second cancer incidence after non-Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study.

Authors:  Elizabeth C Bluhm; Cécile Ronckers; Robert J Hayashi; Joseph P Neglia; Ann C Mertens; Marilyn Stovall; Anna T Meadows; Pauline A Mitby; John A Whitton; Sue Hammond; Joseph D Barker; Sarah S Donaldson; Leslie L Robison; Peter D Inskip
Journal:  Blood       Date:  2008-02-07       Impact factor: 22.113

10.  The cumulative burden of surviving childhood cancer: an initial report from the St Jude Lifetime Cohort Study (SJLIFE).

Authors:  Nickhill Bhakta; Qi Liu; Kirsten K Ness; Malek Baassiri; Hesham Eissa; Frederick Yeo; Wassim Chemaitilly; Matthew J Ehrhardt; Johnnie Bass; Michael W Bishop; Kyla Shelton; Lu Lu; Sujuan Huang; Zhenghong Li; Eric Caron; Jennifer Lanctot; Carrie Howell; Timothy Folse; Vijaya Joshi; Daniel M Green; Daniel A Mulrooney; Gregory T Armstrong; Kevin R Krull; Tara M Brinkman; Raja B Khan; Deo K Srivastava; Melissa M Hudson; Yutaka Yasui; Leslie L Robison
Journal:  Lancet       Date:  2017-09-08       Impact factor: 79.321

View more
  2 in total

1.  Non-Hodgkin lymphoma after pediatric kidney transplantation.

Authors:  Ryszard Grenda
Journal:  Pediatr Nephrol       Date:  2021-10-11       Impact factor: 3.651

2.  High percentages of peripheral blood T-cell activation in childhood Hodgkin's lymphoma are associated with inferior outcome.

Authors:  Fengqing Cai; Hui Gao; Zhongsheng Yu; Kun Zhu; Weizhong Gu; Xiaoping Guo; Xiaojun Xu; Hongqiang Shen; Qiang Shu
Journal:  Front Med (Lausanne)       Date:  2022-08-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.